<doc>
  <docmeta id="113hr1150ih">
    <bill congress="113" type="hr" number="1150" version="ih"/>
    <revision size="25801" annotations="0" id="12" commit-time="2013-04-15T14:28:34+00:00" committer="favila" doc="113hr1150ih/12.xml" status="complete">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H43E6A9A134B844788FE7B4136905D95C" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 1150 IH: Preservation of Antibiotics for Medical Treatment Act of 2013</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-03-14</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1150</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130314">March 14, 2013</action-date>
			<action-desc>
        <sponsor name-id="S000480">Ms. Slaughter</sponsor>
			 introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to
		  preserve the effectiveness of medically important antimicrobials used in the
		  treatment of human and animal diseases.</official-title>
	</form>
	<legis-body id="HBD4A645823F04386A0B52903F778D522" style="OLC">
		<section id="H31F72AF810FF45438D365278EDD8A63B" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Preservation of Antibiotics for
			 Medical Treatment Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H0D39B9940E9540168E421C3AF6E43360">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">The Congress finds the following:</text>
			<paragraph id="H7471AAFF10B94B359C0989567BCF16E1">
        <enum>(1)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="HECBCC072259B48F281ADEC19BA71C970">
          <enum>(A)</enum>
          <text>In 1977, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
			 Drug Administration</cato:entity-ref> concluded that feeding livestock low doses of antibiotics
			 used in human disease treatment could promote the development of
			 antibiotic-resistance in bacteria. However, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
			 did not act in response to these findings, despite laws requiring the agency to
			 do so.</text>
				</subparagraph>
        <subparagraph id="HD48CA5749A4B4D898093E9D9933E8086" indent="up1">
          <enum>(B)</enum>
          <text>In 2012, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug
			 Administration</cato:entity-ref> was ordered by a Federal court to address the use of antibiotics
			 in livestock, as the result of a lawsuit filed against the agency citing the
			 agency’s failure to act in response to the 1977 findings.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HF2EEF440566D4B02AAA567ABBBAA5F84">
        <enum>(2)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="H20B636BFA3334EC5940E633B9D066F36">
          <enum>(A)</enum>
          <text>In 1998, the National
			 Academy of Sciences noted that antibiotic-resistant bacteria generate a minimum
			 of $4,000,000,000 to $5,000,000,000 in costs to United States society and
			 individuals yearly.</text>
				</subparagraph>
        <subparagraph id="HC0917E10669849DF8586AB9DADC0CFF2" indent="up1">
          <enum>(B)</enum>
          <text>In 2009, Cook County Hospital and the
			 Alliance for Prudent Use of Antibiotics estimated that the total health care
			 cost of antibiotic resistant infections in the United States was between
			 $16,600,000,000 and $26,000,000,000 annually.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="H9F158C47A05542ACBAB484C323876AC3">
        <enum>(3)</enum>
        <text>An April 1999
			 study by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Government Accountability Office</cato:entity-ref> concluded that resistant strains
			 of 3 microorganisms that cause food-borne illness or disease in humans
			 (Salmonella, Campylobacter, and E. coli) are linked to the use of antibiotics
			 in animals.</text>
			</paragraph>
      <paragraph id="H2D57DEFE85BE4B72AFC52B143881F488">
        <enum>(4)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="HA795F2B98D83424CADB41DD6980512B7">
          <enum>(A)</enum>
          <text>Large-scale, voluntary
			 surveys by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Department of Agriculture</cato:entity-ref>’s Animal and Plant Health Inspection
			 Service in 1999, 2001, and 2006 revealed that—</text>
					<clause id="HA1C13C474754420A8E2CAD4012D2EC35" indent="up1">
            <enum>(i)</enum>
            <text>84 percent of grower-finisher swine
			 farms, 83 percent of cattle feedlots, and 84 percent of sheep farms administer
			 antimicrobials in the feed or water for health or growth promotion reasons;
			 and</text>
					</clause>
          <clause id="HC6D72AD182794FF8A1DD1CC0C254F9C6" indent="up1">
            <enum>(ii)</enum>
            <text>many of the antimicrobials
			 identified are identical or closely related to drugs used in human medicine,
			 including tetracyclines, macrolides, Bacitracin, penicillins, and sulfonamides;
			 and</text>
					</clause>
        </subparagraph>
        <subparagraph id="H56D1035DB5EC4804AC296761AFF62BBF" indent="up1">
          <enum>(B)</enum>
          <text>these drugs are used in people to
			 treat serious diseases such as pneumonia, scarlet fever, rheumatic fever,
			 sexually transmitted infections, skin infections, and even pandemics like
			 malaria and plague, as well as bioterrorism agents like smallpox and
			 anthrax.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="H081D1D683E8D4332A8CAF4016CB53F8A">
        <enum>(5)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="HCBFE13D291CB408B904A0F6CE05CDF25">
          <enum>(A)</enum>
          <text>Any overuse or misuse of
			 antibiotics contributes to the spread of antibiotic resistance, whether in
			 human medicine or in agriculture.</text>
				</subparagraph>
        <subparagraph id="H059E1AA384174ABD9EEA1FFF09E5C399" indent="up1">
          <enum>(B)</enum>
          <text>Recognizing the public health threat
			 caused by antibiotic resistance, Congress took several steps to curb antibiotic
			 overuse in human medicine through amendments to the <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Public Health Service Act">Public Health Service Act</cato:entity-ref>
			 (<external-xref legal-doc="usc" parsable-cite="usc/42/201">
                <cato:entity-ref entity-type="uscode" value="usc/42/201/etseq">42 U.S.C. 201 et seq.</cato:entity-ref>
              </external-xref>
            </cato:entity>) made by <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Public Health Threats and Emergencies Act/s:102">section 102 of the Public Health Threats and
			 Emergencies Act</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/106/505">
                <external-xref legal-doc="public-law" parsable-cite="pl/106/505">Public Law 106–505</external-xref>, title I</cato:entity-ref>; <cato:entity-ref entity-type="statute-at-large" value="statute-at-large/114/2315">114 Stat. 2315</cato:entity-ref>)</cato:entity>, but has not yet
			 addressed antibiotic overuse in agriculture.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HA8EA3834C3184F57B85BAAA0387A3758">
        <enum>(6)</enum>
        <text>In January 2001, a
			 Federal interagency task force—</text>
				<subparagraph id="H5F954BF2B94E4F4D95AC20CE980ED9F9">
          <enum>(A)</enum>
          <text>released an action
			 plan to address the continuing decline in effectiveness of antibiotics against
			 common bacterial infections, referred to as antibiotic resistance;</text>
				</subparagraph>
        <subparagraph id="HDA61A7A17BD74E1CA4FF661846BA2914">
          <enum>(B)</enum>
          <text>determined that
			 antibiotic resistance is a growing menace to all people and poses a serious
			 threat to public health; and</text>
				</subparagraph>
        <subparagraph id="H3749189634B84799A1D289C9C7994F30">
          <enum>(C)</enum>
          <text>cautioned that if
			 current trends continue, treatments for common infections will become
			 increasingly limited and expensive, and, in some cases, nonexistent.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="H0920E6AE5B5045A49CAC36AA6BDA1621">
        <enum>(7)</enum>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1434">United States
			 Geological Survey</cato:entity-ref> reported in March 2002 that—</text>
				<subparagraph id="H22AB292129B74AC49B2DDDA7A3EA63D8">
          <enum>(A)</enum>
          <text>antibiotics were
			 present in 48 percent of the streams tested nationwide; and</text>
				</subparagraph>
        <subparagraph id="H2E818F3072234CC2996CA8B3DD02B18F">
          <enum>(B)</enum>
          <text>almost half of the
			 tested streams were downstream from agricultural operations.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HCD522506C63A4508AB117F113AB636AF">
        <enum>(8)</enum>
        <text>The peer-reviewed
			 journal <quote>Clinical Infectious Diseases</quote> published a report in June
			 2002 that—</text>
				<subparagraph id="HECB6062BA06F4F3484F424F3E26C6C55">
          <enum>(A)</enum>
          <text>was based on a
			 2-year review by experts in human and veterinary medicine, public health,
			 microbiology, biostatistics, and risk analysis, of more than 500 scientific
			 studies on the human health impacts of antimicrobial use in agriculture;
			 and</text>
				</subparagraph>
        <subparagraph id="H0F8E7002B90645799A89F4E1A1CD3481">
          <enum>(B)</enum>
          <text>recommended that
			 antimicrobial agents should no longer be used in agriculture in the absence of
			 disease, but should be limited to therapy for diseased individual animals and
			 prophylaxis when disease is documented in a herd or flock.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HBDB9002730F848E3ADE768D88DB7C66E">
        <enum>(9)</enum>
        <text>In a March 2003
			 report, the National Academy of Sciences stated that—</text>
				<subparagraph id="HC4532FACBC0D4A65BCC9B9FE9EB244EF">
          <enum>(A)</enum>
          <text>a decrease in
			 antimicrobial use in human medicine alone will have little effect on the
			 current situation; and</text>
				</subparagraph>
        <subparagraph id="H1492929C313E4E75AE5A4A23756875D5">
          <enum>(B)</enum>
          <text>substantial
			 efforts must be made to decrease inappropriate overuse in animals and
			 agriculture.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="H2C8EA9C1E442451EAC1BC9D96E5DEFA5">
        <enum>(10)</enum>
        <text>The <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food,
			 Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/301">
              <cato:entity-ref entity-type="uscode" value="usc/21/301/etseq">21 U.S.C. 301 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>—</text>
				<subparagraph id="H027B21D67105491BADB6DF54AB815E70">
          <enum>(A)</enum>
          <text>requires that all
			 drugs be shown to be safe before the drugs are approved; and</text>
				</subparagraph>
        <subparagraph id="HF47E6E0D47FF40C797EED165412D6719">
          <enum>(B)</enum>
          <text>places the burden
			 on manufacturers to account for health consequences and prove safety.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HAA02866992464DB7B29A748D74283A3A">
        <enum>(11)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="H691454AD26BA4B588139CD11248B39AD">
          <enum>(A)</enum>
          <text>In 2003, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and
			 Drug Administration</cato:entity-ref> modified the drug approval process for antibiotics to
			 recognize the development of resistant bacteria as an important aspect of
			 safety, but most antibiotics currently used in animal production systems for
			 nontherapeutic purposes were approved before the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>
			 began considering resistance during the drug-approval process.</text>
				</subparagraph>
        <subparagraph id="HDD68A150B5A042DFB9520013E86A618E" indent="up1">
          <enum>(B)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> has
			 not established a schedule for reviewing those existing approvals.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HF8619BBE79504ECEAFC08C9E1A945EBB">
        <enum>(12)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="H977A87F7CF004673895C016E7827EF8B">
          <enum>(A)</enum>
          <text>In an April 2004 report,
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Government Accountability Office</cato:entity-ref>—</text>
					<clause id="H28B82A8B14E74F519A2C90523CB0F439" indent="up1">
            <enum>(i)</enum>
            <text>concluded that Federal agencies do
			 not collect the critical data on antibiotic use in animals that they need to
			 support research on human health risks; and</text>
					</clause>
          <clause id="H7378768DFAFE4FB59B99BDB1CD370E10" indent="up1">
            <enum>(ii)</enum>
            <text>recommended that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Department of
			 Agriculture</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Department of Health and Human Services</cato:entity-ref> develop and
			 implement a plan to collect data on antibiotic use in animals.</text>
					</clause>
        </subparagraph>
        <subparagraph id="H178E444AEBFA4B9EB0F8BD52BB014493" indent="up1">
          <enum>(B)</enum>
          <text>In a September 2011 update to that
			 report, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0500">Government Accountability Office</cato:entity-ref>—</text>
					<clause id="H8FA85011BF7F4134BC79B61BA705934A">
            <enum>(i)</enum>
            <text>concluded that Federal agencies had
			 made limited progress in addressing antibiotic use in animals;</text>
					</clause>
          <clause id="HB1939AD1E29C4D6C876F52AAC04014F6">
            <enum>(ii)</enum>
            <text>recommended that Federal agencies
			 fund research on alternatives to current antibiotic use practices; and</text>
					</clause>
          <clause id="H1161EAF1413D4B128B262A5740A2AB6B">
            <enum>(iii)</enum>
            <text>recommended that Federal agencies
			 track the effectiveness of policies that curb antibiotic resistance, including
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">FDA</cato:entity-ref>’s voluntary guidelines reducing antibiotic use in food animals.</text>
					</clause>
        </subparagraph>
      </paragraph>
      <paragraph id="H38A40CDAEAD64DCE81331A3DEA35B0AE">
        <enum>(13)</enum>
        <text>In 2009, the
			 Congressional Research Service concluded that without restrictions on the use
			 of antimicrobial drugs in the production of livestock, export markets for
			 livestock and poultry could be negatively impacted due to restrictions on the
			 use of antibiotics in other nations.</text>
			</paragraph>
      <paragraph id="H77D6E51A63554A1C9A31DD5BD3E0D92E">
        <enum>(14)</enum>
        <text>In 2010, the
			 peer-reviewed journal <quote>Molecular Cell</quote> published a study
			 demonstrating that low-dosage use of antibiotics causes a dramatic increase in
			 genetic mutation, raising new concerns about the agricultural practice of using
			 low-dosage antibiotics in order to stimulate growth promotion and routinely
			 prevent disease in unhealthy conditions.</text>
			</paragraph>
      <paragraph id="HC18F715C09944D3D80AD2A7AF15706CB">
        <enum>(15)</enum>
        <text>In 2010, the
			 Danish Veterinary and Food Administration testified that the Danish ban of the
			 nontherapeutic use of antibiotics in food animal production resulted in a
			 marked reduction in antimicrobial resistance in multiple bacterial species,
			 including Campylobacter and Enterococci.</text>
			</paragraph>
      <paragraph id="HBE7306DEEE884DEFB4249C84D883B20F">
        <enum>(16)</enum>
        <text>In 2011, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
			 and Drug Administration</cato:entity-ref> determined that—</text>
				<subparagraph id="H0FB7812190EB4FF392F967F14DEBBC3F">
          <enum>(A)</enum>
          <text>13.5 million
			 kilograms of antibacterial drugs were sold for use on food animals in the
			 United States in 2010;</text>
				</subparagraph>
        <subparagraph id="HB33E3863082F4992907CD04AD7F16479">
          <enum>(B)</enum>
          <text>3.3 million
			 kilograms of antibacterial drugs were used for human health in 2010; and</text>
				</subparagraph>
        <subparagraph id="HDB6EAB8CDDC445DE870AFB6D26BE1035">
          <enum>(C)</enum>
          <text>therefore, 80
			 percent of antibacterial drugs disseminated in the United States in 2010 were
			 sold for use on food animals, rather than being used for human health.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HE5F975E915934BC1AE5AF6938A9D86F9">
        <enum>(17)</enum>
        <text>In 2011, a review
			 of all scientific studies on antimicrobial use in farm animals, published in
			 Clinical Microbiology Reviews, found that—</text>
				<subparagraph id="HA63082A1D4474959B8BD524DDF71C25F">
          <enum>(A)</enum>
          <text>use of antibiotics
			 in food animals leads to development of reservoirs of antibiotic
			 resistance;</text>
				</subparagraph>
        <subparagraph id="HEB3EFA5098F14CF4A9124220336C1BC6">
          <enum>(B)</enum>
          <text>a ban on
			 antibiotic use in food animals would preserve their use for medicine;
			 and</text>
				</subparagraph>
        <subparagraph id="H7B228642303E40D68E65796F7470B276">
          <enum>(C)</enum>
          <text>a Danish ban on
			 antibiotics in food animals resulted in little change in animal morbidity and
			 mortality, and only a modest increase in production cost.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HB142E969E9204A3695D98E3832537E80">
        <enum>(18)</enum>
        <text>In April 2012,
			 the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> issued voluntary guidance to industry on
			 reducing antibiotic use in livestock and poultry. As part of that guidance, it
			 summarized over 35 years of peer-reviewed scientific literature regarding use
			 of antimicrobial drugs in livestock. As a result, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">FDA</cato:entity-ref> stated strategies for
			 controlling antibiotic resistance are needed, and are seeking voluntarily
			 limits on antibiotic use.</text>
			</paragraph>
      <paragraph id="H53E1AE89D88E4848B043B4D8D6E3736D">
        <enum>(19)</enum>
        <subparagraph commented="no" display-inline="yes-display-inline" id="H3F28C0EDD9E24F51B61485F85DDA4E17">
          <enum>(A)</enum>
          <text>In January 2013,
			 Consumer Reports published test results on pork products bought in grocery
			 stores nationwide showing disturbingly high levels of Salmonella and Yersinia
			 enterocolitica bacteria that were resistant to the antibiotics used to treat
			 food borne illnesses. A 2003 Consumer Report study showed similar results in
			 poultry products.</text>
				</subparagraph>
        <subparagraph id="H7EFBB75AB32C4034AFF439A1FC9042C2" indent="up1">
          <enum>(B)</enum>
          <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>’s
			 National Antimicrobial Resistance Monitoring System routinely finds that retail
			 meat products are contaminated with bacteria (including the foodborne pathogens
			 Campylobacter and Salmonella) that are resistant to antibiotics important in
			 human medicine. The 2011 National Antimicrobial Resistance Monitoring System
			 report found that the percentage of meat containing antibiotic resistant
			 bacteria increases each year and that many of these bacteria exhibit multiple
			 antibiotic resistance.</text>
				</subparagraph>
      </paragraph>
      <paragraph id="HE65A279F891F4FBFACE173C7B94BB9BF">
        <enum>(20)</enum>
        <text>Antibiotic
			 resistance, resulting in a reduced number of effective antibiotics, may
			 significantly impair the ability of the United States to respond to terrorist
			 attacks involving bacterial infections or a large influx of hospitalized
			 patients.</text>
			</paragraph>
      <paragraph id="HCB28D12EDC144A00980849F46D8453F6">
        <enum>(21)</enum>
        <text>Many scientific
			 studies confirm that the nontherapeutic use of antibiotics in agricultural
			 animals contribute to the development of antibiotic-resistant bacterial
			 infections in people.</text>
			</paragraph>
      <paragraph id="H5DC8017AE1404E0CB633EE82493DF4CB">
        <enum>(22)</enum>
        <text>Epidemiological
			 research has shown that resistant Salmonella and Campylobacter infections are
			 associated with increased numbers of ill patients and bloodstream infections,
			 and increased death.</text>
			</paragraph>
      <paragraph id="H4DAE6857B0924281BC39DF279062AD5D">
        <enum>(23)</enum>
        <text>The American
			 Medical Association, the American Public Health Association, the National
			 Association of County and City Health Officials, and the National Sustainable
			 Agriculture Coalition are among the over 400 organizations representing health,
			 consumer, agricultural, environmental, humane, and other interests that have
			 supported enactment of legislation to phase out nontherapeutic use in farm
			 animals of medically important antimicrobials.</text>
			</paragraph>
    </section>
    <section id="H79549DAE2C4E4302BFDFD268E2F21071">
      <enum>3.</enum>
      <header>Purpose</header>
      <text display-inline="no-display-inline">The purpose of this Act is to preserve the
			 effectiveness of medically important antimicrobials used in the treatment of
			 human and animal diseases.</text>
		</section>
    <section id="H8622D991CFD84C93AFFB17E342DE050A">
      <enum>4.</enum>
      <header>Proof of safety
			 of medically important antimicrobials</header>
			<subsection id="HF2A8078D34EF41DBB09055B5D9519C6F">
        <enum>(a)</enum>
        <header>Applications
			 pending or submitted after enactment</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1">Section 512(d)(1) of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">
              <cato:entity-ref entity-type="uscode" value="usc/21/360b/d/1">21 U.S.C. 360b(d)(1)</cato:entity-ref>
            </external-xref>)</cato:entity> is amended—</text>
				<paragraph id="HDCAAE38161384355A993DE33D7F5109E">
          <enum>(1)</enum>
          <text>in the first
			 sentence—</text>
					<subparagraph id="H25F1E62275C84A8E8A7B23232457EC06">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1/sp:H">subparagraph
			 (H)</cato:entity-ref>, by striking <quote>or</quote> at the end;</text>
					</subparagraph>
          <subparagraph id="H4E7384A50574489D9A04E3B89A55DB6D">
            <enum>(B)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1/sp:I">subparagraph
			 (I)</cato:entity-ref>, by inserting <quote>or</quote> at the end; and</text>
					</subparagraph>
          <subparagraph id="H5B3E05DD3BD9474AB1255052B999C902">
            <enum>(C)</enum>
            <text>by inserting after
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1/sp:I">subparagraph (I)</cato:entity-ref> the following:</text>
						<quoted-block id="H7DBB8DA351664928927920ACCE183690" style="OLC">
							<subparagraph id="HD2DA9C9482C0498387E774830E8E4A2B">
                <enum>(J)</enum>
                <text>with respect to a
				medically important antimicrobial (as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q" proposed="true">subsection (q)</cato:entity-ref>), the applicant
				has failed to demonstrate that there is a reasonable certainty of no harm to
				human health due to the development of antimicrobial resistance that is
				attributable, in whole or in part, to the nontherapeutic use (as defined in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q" proposed="true">subsection (q)</cato:entity-ref>) of the medically important antimicrobial or
				drug;</text>
							</subparagraph>
              <after-quoted-block>;
				and</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="H2369384792E64BF2AAE755401B1E6336">
          <enum>(2)</enum>
          <text>in the second
			 sentence, by striking <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1/sp:A..I">(A) through (I)</cato:entity-ref>
            </quote> and inserting <quote>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:d/p:1/sp:A..J" proposed="true">(A)
			 through (J)</cato:entity-ref>
            </quote>.</text>
				</paragraph>
      </subsection>
      <subsection id="H0AD6E75193CE4D049107DBB187E8BCB9">
        <enum>(b)</enum>
        <header>Phased
			 elimination of nontherapeutic use in animals of medically important
			 antimicrobials</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">Section 512 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/360b">
              <cato:entity-ref entity-type="uscode" value="usc/21/360b">21 U.S.C. 360b</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at the end the
			 following:</text>
				<quoted-block id="H0032508606FA496AB9891225265DDC2C" style="OLC">
					<subsection id="HC2CF2463631B4195AFCCF82ECB3F0A2F">
            <enum>(q)</enum>
            <header>Phased
				elimination of nontherapeutic use in animals of medically important
				antimicrobials</header>
						<paragraph id="H194FDEE1648841B4A4E6CFEFE77CE31D">
              <enum>(1)</enum>
              <header>Applicability</header>
              <text>This
				paragraph applies to the nontherapeutic use in a food-producing animal of a
				drug—</text>
							<subparagraph id="HB7AB4C61985C4CE696ED2541EB89CBD3">
                <enum>(A)</enum>
                <text>that is a
				medically important antimicrobial; or</text>
							</subparagraph>
              <subparagraph id="H41862A6C7D9C4710BB38B03ED3BD856F">
                <enum>(B)</enum>
                <clause commented="no" display-inline="yes-display-inline" id="H5721EBEA666C4931835D5334FFED9191">
                  <enum>(i)</enum>
                  <text>for which there is in
				effect an approval of an application or an exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">subsection (b)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">(i)</cato:entity-ref>,
				or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">(j) of section 505</cato:entity-ref>; or</text>
								</clause>
                <clause id="H8434ED9E83804792869AB964D339AE7B" indent="up1">
                  <enum>(ii)</enum>
                  <text>that is otherwise marketed for
				human use.</text>
								</clause>
              </subparagraph>
            </paragraph>
            <paragraph id="H7957C19A34A94E9B9D0E22CCCC6A69A4">
              <enum>(2)</enum>
              <header>Withdrawal</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> shall withdraw the approval of a nontherapeutic use in food-producing
				animals of a drug described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:1" proposed="true">paragraph (1)</cato:entity-ref> on the date that is 2 years after
				the date of enactment of this subsection unless—</text>
							<subparagraph id="H99AA7430D712415F9B4C63181BE1F8DF">
                <enum>(A)</enum>
                <text>before the date
				that is 2 years after the date of the enactment of this subsection, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> makes a final written determination that the holder of the approved
				application has demonstrated that there is a reasonable certainty of no harm to
				human health due to the development of antimicrobial resistance that is
				attributable in whole or in part to the nontherapeutic use of the drug;
				or</text>
							</subparagraph>
              <subparagraph id="H1E6BAEC3B39941C7945D3EA228FE4015">
                <enum>(B)</enum>
                <text>before the date
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> makes a final written
				determination under this subsection, with respect to a risk analysis of the
				drug conducted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> and other relevant information, that there is a
				reasonable certainty of no harm to human health due to the development of
				antimicrobial resistance that is attributable in whole or in part to the
				nontherapeutic use of the drug.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HA9C1575E3794454FBCC4D4377D53C85F">
              <enum>(3)</enum>
              <header>Exemptions</header>
              <text>Except
				as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:5" proposed="true">paragraph (5)</cato:entity-ref>, if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> grants an exemption under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i)</cato:entity-ref> for a drug that is a medically important antimicrobial, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> shall rescind each approval of a nontherapeutic use in a
				food-producing animal of the medically important antimicrobial, as of the date
				that is 2 years after the date on which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> grants the
				exemption.</text>
						</paragraph>
            <paragraph id="HB9EAE4BA53154A53A54AE3C0F557944F">
              <enum>(4)</enum>
              <header>Approvals</header>
              <text>Except
				as provided in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:5" proposed="true">paragraph (5)</cato:entity-ref>, if an application for a drug that is a medically
				important antimicrobial is submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b">section 505(b)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> shall rescind each approval of a nontherapeutic use in a
				food-producing animal of the medically important antimicrobial, as of the date
				that is 2 years after the date on which the application is submitted to the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="HE2C2F483273F4242B84001BC950E9E2B">
              <enum>(5)</enum>
              <header>Exceptions</header>
              <text>
                <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:3" proposed="true">Paragraph
				(3)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:4" proposed="true">(4)</cato:entity-ref>, as the case may be, shall not apply if—</text>
							<subparagraph id="HB768282DA46C4ECA8A2BB99765A5968A">
                <enum>(A)</enum>
                <text>before the date on
				which approval would be rescinded under that paragraph, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> makes a
				final written determination that the holder of the application for the approved
				nontherapeutic use has demonstrated that there is a reasonable certainty of no
				harm to human health due to the development of antimicrobial resistance that is
				attributable in whole or in part to the nontherapeutic use in the
				food-producing animal of the medically important antimicrobial; or</text>
							</subparagraph>
              <subparagraph id="HAEB376E190F74B078D9BECDA88D69C94">
                <enum>(B)</enum>
                <text>before the date
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q/p:5/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> makes a final written
				determination, with respect to a risk analysis of the medically important
				antimicrobial conducted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="1200">Secretary</cato:entity-ref> and any other relevant information,
				that there is a reasonable certainty of no harm to human health due to the
				development of antimicrobial resistance that is attributable in whole or in
				part to the nontherapeutic use of the medically important antimicrobial.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H8345B1B0B472438394492D269DAF97E5">
              <enum>(6)</enum>
              <header>Definition</header>
              <text>In
				this subsection:</text>
							<subparagraph id="HCA28B5A9E2324B55B3EF10A07D6ECD4C">
                <enum>(A)</enum>
                <text>The term
				<term>medically important antimicrobial</term> means a drug that—</text>
								<clause id="H82E049A3B32644AFB987CFC6A9311956">
                  <enum>(i)</enum>
                  <text>is
				intended for use in food-producing animals; and</text>
								</clause>
                <clause id="H8444E9CF213D4DEF9337399D17108667">
                  <enum>(ii)</enum>
                  <text>is composed
				wholly or partly of—</text>
									<subclause id="HED66A36DA17544AFBC37FA805AB89E52">
                    <enum>(I)</enum>
                    <text>any kind of
				penicillin, tetracycline, macrolide, lincosamide, streptogramin,
				aminoglycoside, sulfonamide, or cephalosporin; or</text>
									</subclause>
                  <subclause id="H4E0B81DCAAFB4A6089EF43F3E85077F0">
                    <enum>(II)</enum>
                    <text>a drug from an
				antimicrobial class that is listed as <quote>highly important</quote>,
				<quote>critically important</quote>, or <quote>important</quote> by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="19UH">World
				Health Organization</cato:entity-ref> in the latest edition of its publication entitled
				<quote>Critically Important Antimicrobials for Human Medicine</quote> (or a
				successor publication).</text>
									</subclause>
                </clause>
              </subparagraph>
              <subparagraph id="HBA377744093B48AF989800C197C005BC">
                <enum>(B)</enum>
                <text>The term
				<term>therapeutic use</term>, with respect to a medically important
				antimicrobial, means the use of antimicrobials for the specific purpose of
				treating an animal with a documented disease or infection. Such term does not
				include the continued use of such an antimicrobial in the animal after the
				disease or infection is resolved.</text>
							</subparagraph>
              <subparagraph id="H0904003026DA40A0B125D0979E9E6676">
                <enum>(C)</enum>
                <text>The term
				<term>nontherapeutic use</term>—</text>
								<clause id="H4589D9B88AD54725932EB11C1A0ACAE7">
                  <enum>(i)</enum>
                  <text display-inline="yes-display-inline">means administration of antibiotics to an
				animal through feed and water (or, in poultry hatcheries, through any means)
				for purposes (such as growth promotion, feed efficiency, weight gain, or
				disease prevention) other than therapeutic use or nonroutine disease control;
				and</text>
								</clause>
                <clause id="H0CE62A7E08494AB995E4B32AACA158D3">
                  <enum>(ii)</enum>
                  <text>includes any
				repeated or regular pattern of use of medically important antimicrobials for
				purposes other than therapeutic use or nonroutine disease control.</text>
								</clause>
              </subparagraph>
              <subparagraph id="HF054247501E64F379185EE38DD85A3A4">
                <enum>(D)</enum>
                <text>The term
				<term>noncustomary situation</term> does not include normal or standard
				practice and conditions on the premises that facilitate the transmission of
				disease.</text>
							</subparagraph>
              <subparagraph id="HEF50AD028E6543FE89CF04D8B166AEF8">
                <enum>(E)</enum>
                <text display-inline="yes-display-inline">The term <term>nonroutine disease
				control</term> means the use of antibiotics on an animal that is not sick but
				where it can be shown that a particular disease or infection is present, or is
				likely to occur because of a specific, noncustomary situation, on the premises
				at the barn, house, pen, or other level at which the animal is
				kept.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
    </section>
    <section id="HBBDA23D72DDF48BEBE30D2B5A26B6F17">
      <enum>5.</enum>
      <header>Limitations on
			 use of medically important antimicrobials for nonroutine disease
			 control</header>
			<subsection id="HBC5006A58C6B422D923C12CB0FB12108">
        <enum>(a)</enum>
        <header>Prohibited
			 acts</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301 of the
			 Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
              <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at
			 the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HB07E4CF6A6EE4883AD361B456B5D9658" style="OLC">
					<subsection id="HF777B5A6D1004E0C9E317ECCEE925C4F">
            <enum>(ccc)</enum>
            <text display-inline="yes-display-inline">The administration of a medically important
				antimicrobial to a food-producing animal for nonroutine disease control in
				violation of the requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512A">section
				512A</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="HF4C330E44CC64C569BF765BA6829E1C4">
        <enum>(b)</enum>
        <header>Requirements</header>
        <text display-inline="yes-display-inline">
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V">Chapter V of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512">section 512 of such Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/360b">21 U.S.C.
			 360b</cato:entity-ref>)</cato:entity> the following:</text>
				<quoted-block display-inline="no-display-inline" id="HF9D11212C4BC46D39514BAB341F190E5" style="OLC">
					<section id="H28ADC5A48B4448B2B73ABA9A40475630">
            <enum>512A.</enum>
            <header>Limitations on
				use of medically important antimicrobials for nonroutine disease
				control</header>
						<subsection id="H44583495FFD54A439826FE8C71291E6D">
              <enum>(a)</enum>
              <header>Prohibition</header>
              <text display-inline="yes-display-inline">It shall be unlawful to administer
				(including by means of animal feed) a medically important antimicrobial to a
				food-producing animal for nonroutine disease control unless—</text>
							<paragraph id="H4A34BDAA099641D3B5741EC990388579">
                <enum>(1)</enum>
                <text>there is a
				significant risk that a disease or infection present on the premises will be
				transmitted to the food-producing animal;</text>
							</paragraph>
              <paragraph id="H9DD705F3DC1B4A58A5020437BA9A582C">
                <enum>(2)</enum>
                <text display-inline="yes-display-inline">the administration of the medically
				important antimicrobial to the food-producing animal is necessary to prevent or
				reduce the risk of transmission of the disease or infection described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512A/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>;</text>
							</paragraph>
              <paragraph id="H43B3108EBD9C43E7957B220E767827C3">
                <enum>(3)</enum>
                <text display-inline="yes-display-inline">the medically important antimicrobial is
				administered to the food-producing animal for nonroutine disease control for
				the shortest duration possible to prevent or reduce the risk of transmission of
				the disease or infection described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512A/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref> to the animal; and</text>
							</paragraph>
              <paragraph id="HBEA645DB04974221B2CF8FE5C1A5C65A">
                <enum>(4)</enum>
                <text>the medically
				important antimicrobial is administered—</text>
								<subparagraph id="HB88BAF6EF199413EA89AEB1878CA2532">
                  <enum>(A)</enum>
                  <text>at a scale no
				greater than the barn, house, or pen level; and</text>
								</subparagraph>
                <subparagraph id="H142B958480624D6984D3153B221F830B">
                  <enum>(B)</enum>
                  <text>to the fewest
				animals possible to prevent or reduce the risk of transmission of the disease
				or infection described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512A/ss:a/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
								</subparagraph>
              </paragraph>
            </subsection>
            <subsection id="HA8E5416CC0604458B5E70D9F2DAF017D">
              <enum>(b)</enum>
              <header>Definitions</header>
              <text>In
				this section:</text>
							<paragraph id="H5A5AFAFC6DC64E69B6F311BAE89B9C48">
                <enum>(1)</enum>
                <text>The term
				<term>food-producing animal</term> means a food-producing animal intended for
				sale in interstate commerce.</text>
							</paragraph>
              <paragraph id="HE933310405704112AE590E64592ABEDA">
                <enum>(2)</enum>
                <text>The terms
				<term>medically important antimicrobial</term> and <term>nonroutine disease
				control</term> have the meanings given to such terms in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:512/ss:q" proposed="true">section
				512(q)</cato:entity-ref>.</text>
							</paragraph>
            </subsection>
          </section>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="H781A848210974637852B381EC049906C">
        <enum>(c)</enum>
        <header>Applicability</header>
        <text>The
			 amendments made by this section apply beginning on the date that is 6 months
			 after the date of the enactment of this Act.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>